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Abstract
Objective — To determine if reducing the frequency of urinary sample collection from daily to 5, 3, or 2 days per week during a menstrual
cycle or 28-day amenorrheic monitoring period provide accurate representations of the reproductive hormone metabolites estrone1-glucuronide (E1G) and pregnanediol glucuronide (PdG) exposure and mean concentrations.
Methods — Exercising women presenting with eumenorrhea or exercise-associated menstrual disturbances collected daily urine samples
for the assessment of E1G and PdG concentrations. After enzyme immunoassay analysis of the daily samples, E1G and PdG data were
systematically removed from each menstrual cycle or amenorrheic monitoring period to mimic three reduced collection frequencies,
representing 5, 3, and 2 days per week. Exposure and mean concentration were calculated for both hormones and all four urinary collection frequencies.
Results — E1G and PdG exposure and mean cycle concentrations derived from reduced collection frequencies were not different from daily
collection (P>0.05), independent of whether menstrual cycles and monitoring periods were analyzed together or separately. Bland-Altman analysis indicated acceptable agreement between each reduced collection frequency and daily collection.
Conclusions — Compared with daily urinary collection, a reduced collection frequency of 5, 3, or 2 days each week provides accurate E1G and
PdG profiles of collection periods of various lengths and types of menstrual function. Reduction of urinary sample collection frequency
may enable researchers to reduce participant burden and costs, increase compliance, and study a wider range of study populations.

Hormonal evaluation of the reproductive potential of women
in population based studies most often uses samples of blood
(Ahrens et al., 2014; Jeppesen et al., 2013; Mumford et al.,
2012), urine (De Souza et al., 2010; Direito et al., 2013; McConnell et al., 2002; O’Connor et al., 2003), or saliva (Direito
et al., 2013; Ellison et al., 2007; Kesner et al., 1992; Ziomkiewicz et al., 2008). These assessments are generally limited by
participant training, compliance, and the cost of the assays.
Indeed, the optimal method should yield good participant tolerance and compliance with sample collection while still providing reliable, sensitive, and specific information about the
participants’ reproductive status (Kesner et al., 1992).
In many cases, the use of the gold standard for repeated
assessment of reproductive function, i.e., daily serum sampling which involves invasive blood draws, is not feasible;
therefore, the collection of daily urine samples is an advantageous alternative due to its noninvasive and selfcollectable
nature (Kesner et al., 1995). Daily collection of urine samples
during a menstrual cycle or specified monitoring period provides information about reproductive hormone exposure and
clinical endpoints of reproductive status, such as ovulation
(Baird et al., 1995; Direito et al., 2013; Kassam et al., 1996;
McConnell et al., 2002; O’Connor et al., 2006), pregnancy

(Cate et al., 2013; Greene et al., 2013; Holman et al., 1998;
O’Connor et al., 1998), and menstrual cycle status (De Souza
et al., 2010; Direito et al., 2013; Mallinson et al., 2013b; Mumford et al., 2012; O’Connor et al., 2011; Williams et al., 2010)
in humans and non-human primates. Exposure to reproductive hormones has more recently been shown to be important predictors of general health and disease risk. Measures
of reproductive hormone exposure from daily urinary samples
have been associated with cardiovascular function in amenorrheic exercising women, specifically endothelial dysfunction, bradycardia, low systolic blood pressure, reduced regional blood flow, increased local vascular resistance, and
an unfavorable lipid profile (O’Donnell et al., 2007; Rickenlund et al., 2005; Zeni Hoch et al., 2003). Further, reduced
exposure to estrogen in amenorrheic exercising women, as
assessed by daily urine sample collection, has been associated with increased concentrations of osteoprotegerin, an
important regulator of bone resorption (West et al., 2009),
and clinical measures of bone health (Mallinson et al., 2013a;
Scheid et al., 2011). Risk of ovarian cancer (Parazzini et al.,
1989) and breast cancer (Kossman et al., 2011; Parazzini et
al., 1993) have also been associated with exposure to reproductive hormones.
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Unsupervised participants can easily collect urine samples, thus facilitating monitoring of ovarian function over
extended time periods (Hall Moran et al., 2001). However,
it has been noted that daily urine sample collection presents
a substantial participant burden (Mumford et al., 2011). The
substantial cost of time and participant burden can contribute to increased non-compliance and higher dropout rates
(Mumford et al., 2011). Compliance with daily urinary sample collection is typically high in short-term studies (1–3
months). The potential for reduced compliance increases
over time (Mumford et al., 2011); however, specific data on
participant compliance to urinary collection is scant in publications. For studies lasting between 1 and 3 months, compliance to daily urinary sample collection is in the range
of 92 to 97% (Kesner et al., 1992; Windham et al., 2002;
Wright et al., 1992). For example, Kesner et al. (1992) reported that during a time period of two complete menstrual
cycles, 97% of all scheduled samples were collected. In the
Women’s Reproductive Health Study, 93% of all daily urine
samples were collected over the course of two consecutive
menstrual cycles (Waller et al., 1998).
In studies lasting between 5 and 12 months, compliance
to urinary sample collection is more variable and somewhat
lower, ranging between 50 and 100% (Kravitz et al., 2005;
Liu et al., 2004; Santoro et al., 1996). For example, retrospective analysis of the Study of Women Across the Nation
Daily Hormone substudy, only 680 of 848 eligible participants had collected 80% of the required samples (Kravitz
et al., 2005). In the Semi-Conductor Health Study, where
participants were asked to collect urinary samples daily for
five cycles, only 57% of all cycles had fewer than 3 days of
missing data in any 5-day rolling window (Liu et al., 2004).
In our laboratory, the participants who completed 4 or more
months of a 12-month study collected an average of 90%
of the requested samples; however, individual compliance
ranged from 61 to 100% (unpublished data).
The design of any experiment needs to balance data
quantity and quality while reducing participant burden and
project cost and increasing compliance. To our knowledge,
the only attempt to validate a reduced sampling frequency
for use with urine specimens was conducted by O’Connor et
al. (2006), who evaluated the specificity and sensitivity of
reduced collection frequencies to determine the presence of
ovulation with progesterone glucuronide based algorithms.
The every other day reduced collection frequency accurately
and precisely detected day of ovulation (O’Connor et al.,
2006). Thus, a reduced collection frequency could be useful in conducting research in populations who may be hesitant to participate in research projects that involve daily
urine sampling, such as children or adolescents, and may
aid in collection of urinary samples in locations with limited
cooling and storage capacity. In large-scale and long-term
research studies, reduced collection frequencies would not
only reduce project cost and participant burden but would
also enable researchers to recruit from a larger demographic
area due to the reduced need for storage.
To reduce the burden of collecting daily urinary hormone
specimens and reduce project costs, our goal was to evaluate
if a reduction in the number of collection days from 7 days
per week (i.e., daily sample collection) to 5 (i.e., weekday
sample collection), 3 (i.e., Monday/Wednesday/ Friday), or
2 (i.e., Monday/Thursday) days per week would provide an
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accurate representation of estrone-1-glucuronide (E1G) and
pregnanediol glucuronide (PdG) exposure and mean concentration during an entire menstrual cycle/monitoring period. We chose to evaluate the impact of reduced collection
frequencies on E1G and PdG exposure and mean concentrations because both measures are important predictors of
bone health (Mallinson et al., 2013a; Scheid et al., 2011),
cardiovascular health (O’Donnell et al., 2007; Rickenlund et
al., 2005; Zeni Hoch et al., 2003), and ovarian (Parazzini et
al., 1989) and breast cancer risk (Iversen et al., 2011; Kossman et al., 2011; Parazzini et al., 1993; Terry et al., 2005;
Whelan et al., 1994). We also sought to evaluate if the validity of the reduced sample collection frequencies would be
affected by cycle type (eumenorrheic or amenorrheic) or by
variability of cycle lengths (20–45 days range or 26–36 days
range). As such, the purpose of this analysis was to explore
the average and individual agreement of daily urine sample collection versus sample collection for 5 days, 3 days, or
2 days per week for the following variables: E1G exposure
(area under the curve; AUC), E1G mean concentration, PdG
exposure, and PdG mean concentration. We hypothesized
that E1G and PdG cycle AUC and mean concentration would
be similar when samples were collected daily versus 5 days,
3 days, or 2 days per week for a 28-day monitoring period
or a menstrual cycle with an intermenstrual interval ranging from 20 to 45 days.
Materials and Methods
Experimental design
This study utilizes menstrual cycle data from subjects participating in a study conducted at two sites, University of
Toronto (UT) and the Pennsylvania State University (PSU)
over 8 years. Subjects included women with severe exercise-associated menstrual disturbances (EAMD), including oligomenorrhea (long and inconsistent menstrual cycle
lengths of 36–90 days) and functional hypothalamic amenorrhea (the absence of menses for >90 days). The study
also included a eumenorrheic exercising group (EU) that
served as a control group. Concentrations of reproductive
hormone metabolites were assessed in daily urinary sample collections. The study was approved by the Research
Ethics Board at the UT and the Institutional Review Board
at the PSU. All participants signed an approved informed
consent document.
Participants
Women reporting regular menstrual cycles of 26 to 35 days
for the previous 6 months before the study were recruited
for the EU group, while women reporting no menses in the
previous 3 months, or less than six cycles in the previous 12
months were recruited for the EAMD group. Eligibility criteria for the study included, (1) age 18 to 35 years; (2) weight
stability (±2 kg) for at least 3 months; (3) body mass index (BMI) 16 to 25 kg/m2; (4) good health as determined by
medical exam and no history of any serious medical conditions; (5) no chronic illness, including hyperprolactinemia
and thyroid disease; (6) not currently dieting; (7) no current
clinical diagnosis of an eating disorder or psychiatric disorder; (8) non-smoking, (9) not taking any form of hormonal
therapy for at least 6 months; (10) currently participating
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in ≥2 h/week of purposeful exercise; (11) no history of a
clinical diagnosis of polycystic ovarian syndrome (PCOS);
(12) not pregnant, lactating, or planning a pregnancy; (13)
no medication use that would alter metabolic or reproductive hormone concentrations; and (14) no other contraindications that would preclude participation in the study.

first day of the next menses. From this data set, 79 complete menstrual cycles and 70 28-day monitoring periods

Participant grouping categories
Classification of participant menstrual status (eumenorrheic, oligomenorrheic, or amenorrheic) was based on selfreported menstrual histories and menstrual calendars. Menstrual status was confirmed by urinary concentrations of the
reproductive hormone metabolites, E1G, PdG, and luteinizing hormone (LH).
Demographic assessment
Height (to the nearest 1.0 cm) and weight (to the nearest
0.1 kg) were measured and participants completed questionnaires to assess medical history, exercise and menstrual
history, eating behaviors and psychological health. A physical exam and blood sample were performed to determine
overall health.
Urinary collection procedures
Participants in the EAMD group collected daily urinary samples for a 28-day monitoring period and EU participants collected daily specimens for an entire menstrual cycle. The
EAMD group initiated urinary collection on an arbitrary day
in the study, while the EU group initiated urinary collection
on day 1 or 2 of the menstrual cycle subsequent to demographic assessment. All participants utilized calendars to
record menses and time of urine collection. All urine specimens were labeled with calendar date, cycle/monitoring period number, and cycle/monitoring period day. Participants
stored urine specimens in their household freezers between
drop offs at the laboratory. Frozen ice packs and insulated
lunch packs were used to keep samples cold during transport to the laboratory. In the laboratory urine samples were
stored in a –20°C freezer until analyzed.
Urinary measurement of E1G and PdG
Microtiter plate competitive enzyme immunoassays (EIA)
were used to measure E1G and PdG, as previously described
(De Souza et al., 2010). The secretion of these estrogen and
progesterone metabolites in the urine parallels serum concentrations of the parent hormones (Munro et al., 1991;
O’Connor et al., 2003). Urinary concentrations of E1G and
PdG were corrected for specific gravity, determined using a
hand refractometer (NSG Precision Cells, Inc., Farmingdale,
NY), to account for hydration status (Boeniger et al., 1993;
Haddow et al., 1994; Miller et al., 2004).
Selection of eligible cycles
A flow chart is presented (Fig. 1) to describe the design of
the study and the contribution of participants and cycles
from each study site. A total of 116 participants and 572 cycles/monitoring periods were evaluated for eligibility for
this analysis. There were 63 amenorrheic participants with
267 28-day monitoring periods and 79 eumenorrheic participants with 305 menstrual cycles within the range of
20 to 45 days. Menstrual cycle length was defined as the
number of days from day 1 of menses to the day before the

Figure 1. Number of participants and menstrual cycles/monitoring
periods which contributed to and were excluded from the current
analysis. Data from participants recruited at two study sites, University of Toronto (UT) and the Pennsylvania State University (PSU),
were included. Initially there were 572 menstrual cycles/28-day monitoring periods from 116 participants evaluated for complete sample
collection. Three hundred eighty-two menstrual cycles/monitoring
periods from 61 participants were excluded from the analysis due to
missing collection days. Included in the analysis were 190 menstrual
cycles/monitoring periods from 55 participants, which included 90
menstrual cycles/monitoring periods from 27 participants enrolled
at the UT site and 100 menstrual cycles/monitoring periods from 28
participants enrolled at the PSU site.

(contained no missing samples) that were collected during the
12-month study were used in this analysis. In addition, 41
menstrual cycles with no more than 3 missing days in the
first 6 days of the cycle were also used. In these cases, concentrations of E1G and PdG for the missing days were estimated by averaging the concentrations from the day before and after the missing day. If the missing day was the
first day of the cycle, days 2 to 4 of the cycle were averaged to estimate the concentration for the missing day.
Menstrual cycles included in the complete sample analysis
were a combination of ovulatory (n = 23), luteal phase defect (LPD; n = 43), and anovulatory (n = 54) cycle classifications. Classifications of menstrual cycles were completed
from the original daily specimens and conducted to ensure
inclusion of all types of menstrual cycles in the analysis.
Specific hormonal criteria for classification of ovulatory,
LPD, and anovulatory cycles has been described previously (De Souza et al., 2010). Sixty-one participants and
their 382 menstrual cycles/monitoring periods were excluded from the analysis (Fig. 1). Monitoring periods (used
for amenorrheic women) were excluded if there were any
missing samples. Menstrual cycles (used for eumenorrheic
and oligomenorrheic women) were excluded if there were
more than 3 missing days in the first 6 collection days or
any missing days beyond the first 6 days. Menstrual cycles
were also excluded if the cycle length was outside the 20to 45-day range included in this analysis. The UT site contributed 27 participants and 90 menstrual cycles/monitoring periods to this analysis while the PSU site contributed
28 participants and 100 menstrual cycles/monitoring periods to this analysis (Fig. 1).
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Simulation of reduced number of sample collection days
The daily samples per menstrual cycle/monitoring period
(n = 190) collected by the participants were referenced to
day of the menstrual cycle/monitoring period and collection calendar date. To determine if fewer days of urine collection would provide accurate and precise data for E1G and
PdG exposure and mean concentration during the menstrual
cycle/monitoring period, E1G and PdG data were systematically removed from each menstrual cycle or 28-day monitoring period to mimic a reduced frequency of sample collection
for participants with 100% compliance to daily collection.
The reduced sample collection frequencies were selected to
reduce participant burden and represented three different
collection frequencies as follows: 5 days of urine collection
each week, 3 days of urine collection each week, and 2 days
of urine collection each week. Specifically, for the simulation of collecting five urinary samples per week, E1G and
PdG data for Saturday and Sunday each week of the menstrual cycle/monitoring period were systematically, leaving only the E1G and PdG concentrations from the weekdays
for analysis. For the simulation of collecting three urinary
samples per week, E1G and PdG data were systematically
removed for Tuesday, Thursday, Saturday, and Sunday each
week of the menstrual cycle/monitoring period leaving E1G
and PdG concentrations for Monday, Wednesday, and Friday for the analysis. For simulation of collecting two urinary samples per week, E1G and PdG data were systematically removed for Tuesday, Wednesday, Friday, Saturday,
and Sunday each week of the menstrual cycle/monitoring
period leaving only E1G and PdG concentrations for Monday and Thursday for analysis.
Urinary hormone assessment calculations
E1G and PdG exposures across the menstrual cycle or monitoring period were determined by calculating the AUC for
daily, 5 days, 3 days, and 2 days per week collection frequencies using Kaleidagraph Software (Synergy Software, Reading. PA). Mean E1G and PdG concentrations across the cycle or monitoring period for all collection frequencies were
also calculated.
Statistical analyses
The data presented were obtained at two different locations,
the UT and PSU, over 8 years. E1G and PdG data were analyzed as a merged group of eumenorrheic cycles of 20 to 45
days in length and 28-day amenorrheic monitoring periods
(complete sample analysis; n = 190). Subanalyses of eumenorrheic cycles of 26 to 36 days in length (which is the most
common range of intermenstrual intervals among regularly
menstruating women; n = 94) alone and 28-day amenorrheic monitoring periods (n = 70) alone. Data screening
was conducted before statistical analysis in order to identify
whether the data met the assumptions required by the specific statistical techniques in this analysis. Data screening involved examination of variable distributions within each of
the three analysis groupings for all four collection frequencies (daily, 5 days, 3 days, and 2 days) and all four hormone
variables (E1G AUC, PdG AUC, E1G mean, and PdG mean).
All hormonal variables were found to be not normally distributed. However, logarithmic transformation did not improve normality of these variables. In addition, logarithmic
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transformation was not considered as a practical approach
for Bland-Altman analysis, as the limits of agreement (LOA)
are expressed as multiples of the measured concentration
following logarithmic transformation (Euser et al., 2008).
All data are presented as means6SD, unless otherwise indicated. Linear mixed model ANOVA was used to compare
all ovarian steroid (E1G AUC, E1G mean, PdG AUC, or PdG
mean) data between daily urinary collection and each reduced urinary collection frequency for the complete samples analysis and the eumenorrheic and amenorrheic subanalyses. Since the same individual provided multiple cycles
and/or monitoring periods these data were considered to be
of nested nature; therefore, the participant identifier was
included as a random effect in the linear model. A significance level of α = 0.05 was used to detect differences, and
for multiple comparisons, a was adjusted using Bonferroni
correction. Bland Altman analysis was performed to determine the 95% LOA and to identify potential mean and proportional bias for both AUC and mean concentration (Bland
and Altman, 1995). Errors were calculated as the difference
between daily urinary collection data and each reduced urinary collection data since daily urinary sample collection
was regarded as the criterion method. For convenience,
mean error and lower and upper LOA are also reported as
percent of the average of daily and each reduced urinary collection values. All analyses were conducted using R statistical software (Revolution Analytics, Palo Alto, CA).
Results
Complete sample analysis
In total, there were 55 participants and 190 menstrual cycles (20–45 days in length) and 28-day monitoring periods
with complete data. There were 120 menstrual cycles and 70
28-day amenorrheic monitoring periods. The participants
were aged 22.6±64.3 years, weighed 57.0±6.6 kg, were
164.3±6.6 cm tall, and had a BMI of 21.1±2.0 kg/m2. The
average age at menarche was 13.2±1.6 years and the mean
gynecologic age was 9.5±4.6 years.
Mixed model analysis
Composite graphs of the average E1G and PdG concentrations, respectively, across the entire cycle/monitoring period for daily, 5-day, 3-day, and 2-day collection frequencies
are shown in Figure 2A, B. The average AUC and cycle mean
concentration for each urinary collection frequency are displayed in inset bar graphs within the composite graphs and
in Table 1. There were no significant differences detected
between daily collection and each reduced collection frequency (P > 0.99) with regard to E1G mean concentration;
however, E1G AUC for 2 days per week collection was significantly lower when compared with E1G AUC for daily collection (P > 0.046). There were no significant differences detected between daily collection and each reduced collection
frequency (5 days, 3 days, or 2 days per week) with regard
to PdG AUC (P > 0.050) or mean concentration (P > 0.99).
Bland Altman analysis
On average, the reduced urine collection frequencies for
the complete sample analysis underestimate the daily E1G
AUC by 1.4% for the 5-day collection frequency, 3.2% for
the 3-day collection frequency, and by 8.2% for the 2- day
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Figure 2. Composite graphs of urinary reproductive hormone excretion of E1G (A) and PdG (B) for eumenorrheic cycles of 20 to 45 days in
length and 28-day amenorrheic monitoring periods for daily, 5-day/week, 3-day/week, and 2-day/week urinary collection frequencies. The
inset bar graphs depict the cycle AUC and mean concentration for E1G and PdG for daily, 5-day/week, 3-day/week, and 2-day/week collection frequencies. Cycle day 1 represents the first day of menses. The data points for the central cycle/monitoring period days have an n 5
190. Cycle/monitoring period days at the beginning and end of the composite graphs have a variable “n” due to the varying lengths of the
cycles included in the sample. E1G, estrone-1-glucuronide; PdG, pregnanediol glucuronide; AUC, area under the curve. *Statistical difference (P < 0.05) between daily collection and 2 days per week collection frequency.

collection frequency. The 5-day collection frequency demonstrated the lowest degree of underestimation and 2-day
collection frequency demonstrated the greatest degree of
underestimation when compared with daily sample collection. The E1G AUC for all reduced collection frequencies
demonstrate good agreement with daily urine collection as
indicated by the inclusion of zero in the 95% LOA for the
Bland Altman analyses. The best agreement was observed
with the 5-day collection frequency, indicated by the smallest range for the 95% LOA (see Fig. 3A–C). A proportional
bias was observed in all reduced collection frequencies
(P < 0.010) indicating larger AUC values are, on average, underestimated more than smaller AUC values in all reduced

collection frequencies compared with daily urine collection
(see Table 2).
On average, reduced sample collection underestimated
the daily PdG AUC by 0.6% for the 5-day collection frequency, 2.9% for the 3-day collection frequency, and by
10.8% for the 2-day collection frequency (see Fig. 3D–F
and Table 3). The 5-day collection frequency demonstrated
the lowest degree of underestimation of daily sampling,
while the 2-day collection frequency demonstrated the
greatest degree of underestimation. The PdG AUC for all reduced collection frequencies demonstrate good agreement
with daily urine collection as indicated by the 95% LOA including zero. The best agreement was observed with 5-day

R e d u c t i o n s i n U r i n a ry C o l l e c t i o n F r e q u e n c y
collection frequency, indicated by the smallest range for the
95% LOA. A proportional bias was not observed in the 5-day
and 3-day collection frequencies (P = 0.10), while a proportional bias was observed in the 2-day collection frequency
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(P < 0.000) indicating larger AUC values are, on average,
underestimated more than smaller AUC values in the 2-day
collection frequency compared with daily urine collection
(see Table 3).

Table 1. Reproductive steroid hormone metabolite parameters for the all cycles, eumenorrheic cycles only, and amenorrheic monitoring
periods only analyses for all collection frequencies
Reduced collection frequency
		

Daily

5-d/wk

3-d/wk

2-d/wk

		

Mean±SE

Mean±SE

Mean±SE

Mean±SE

All cycles and monitoring periods (n = 190)
E1G cycle mean AUC (ng × day/mL)
E1G cycle mean concentration (ng/mL)
PdG cycle mean AUC (mg × day/mL)
PdG cycle mean concentration (mg/mL)

856.0±36.3
29.5±1.2
50.0±2.7
1.7±0.1

844.0±35.3
29.6±1.2
49.6±2.8
1.8±0.1

829.0±35.1
29.7±1.2
48.5±2.7
1.8±0.1

789.0.±34.2a
29.6±1.2
44.8±2.5b
1.7±0.1

Eumenorrheic cycles (n = 94)
E1G cycle mean AUC (ng × day/mL)
E1G cycle mean concentration (ng/mL)
PdG cycle mean AUC (mg × day/mL)
PdG cycle mean concentration (mg/mL)

1,037.5±50.7
35.7±1.7
68.4±4.2
2.4±0.1

1,027.5±50.5
35.9±1.7
68.4±4.2
2.4±0.2

1,014.7±50.7
36.2±1.7
67.0±4.1
2.4±0.2

972.5±49.2
36.2±1.8
62.2±4.0b
2.4±0.2

Amenorrheic periods (n = 70)
E1G cycle mean AUC (ng × day/mL)
E1G cycle mean concentration (ng/mL)
PdG cycle mean AUC (mg × day/mL)
PdG cycle mean concentration (mg/mL)

539.2±27.7
20.0±1.0
25.6±1.6
1.0±0.1

532.6±27.3
20.0±1.0
25.2±1.6
1.0±0.1

515.5±26.5
20.0±1.0
24.2±1.5
0.9±0.1

488.6±27.5
20.0±1.1
22.7±1.5
0.9±0.1

Reproductive steroid metabolite parameters include estrone-1-glucuonoide (E1G) and pregnanediol glucuronide (PdG) area under the
curve (AUC) and mean concentration. d/wk, days per week.
a. Significant differences (P<0.05) between the reduced collection frequency and daily collection frequency.
b. A trend for a difference (P<0.1) between the reduced collection frequency and daily collection frequency.

Figure 3. Bland Altman plots for all cycles 20 to 45 days in length and 28-day monitoring periods. The difference between daily and reduced collection frequencies are plotted against the mean of the daily and reduced collection frequency in the 190 paired measurements
from the all cycles/monitoring periods analysis. The comparison of daily and 5 days/week collection frequency is in column 1, daily and 3
days/week collection frequency is in column 2, and daily and 2 days/week collection frequency is in column 3. Differences between daily
and the reduced collection frequencies for E1G AUC (A-C) and PdG AUC (D-F) are demonstrated.
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On average, daily E1G mean concentration was overestimated by 0.5% for the 5-day collection frequency, 0.8%
for the 3-day collection frequency, and by 0.4% for the 2day collection frequency (see Fig. 4A–C and Table 4). The
2-day collection frequency demonstrated the lowest degree
of overestimation of daily sampling, while the 3- day collection frequency demonstrated the greatest degree of overestimation. The E1G cycle mean concentration for all reduced
collection frequencies demonstrate good agreement with
daily urine collection as indicated by the 95% LOA including zero. The best agreement was observed with the 5-day
collection frequency, indicated by the smallest range for the
95% LOA. A proportional bias was not observed in the 5-day
and 3-day collection frequencies (P > 0.60), while a proportional bias was observed in the 2-day collection frequency
(P = 0.040) indicating greater cycle mean concentrations
are, on average, overestimated more than smaller mean cycle concentrations in 2-day collection frequency compared
with daily collection (see Table 4).
Daily PdG mean concentration was overestimated by
2.2% for the 5-day collection frequency and 2.1% for the
3-day collection frequency, while the 2-day collection frequency underestimated the daily PdG mean concentration by

0.2% (see Fig. 4D–F and Table 5). The 5-day collection frequency demonstrated the greatest degree of overestimation
of daily sample collection, while the 2-day collection frequency demonstrated underestimation of daily sample collection. The PdG cycle mean concentration for all reduced
collection frequencies demonstrate good agreement with
daily urine collection as indicated by the 95% LOA including zero. The best agreement was observed with the 5-day
collection frequency, indicated by the smallest range for the
95% LOA. A proportional bias was observed in the 5-day and
3-day collection frequencies (P < 0.010) indicating greater
cycle mean concentrations are, on average, overestimated
compared with daily urine collection, while a trend toward
a proportional bias was observed in the 2-day collection frequency (P = 0.060; see Table 5).
Subanalysis of eumenorrheic cycles
A subanalysis of eumenorrheic menstrual cycles of 26 to 36
days in length included 31 participants and 94 menstrual cycles with complete data. This subanalysis included anovulatory (n = 14), LPD (n = 31), and ovulatory (n = 49) menstrual cycles, which were classified using daily collection
frequency hormonal measurements. The participants were

Table 2. Bland-Altman analysis for all menstrual cycle/monitoring period analyses of E1G AUC
Bland-Altman analysis
Mean
difference
Method

(ng x day/mL) %

All cycles and monitoring periods (n = 190)
Daily vs. 5-d/wk
Daily vs. 3-d/wk
Daily vs. 2-d/wk
Eumenorrheic cycles (n = 94)
Daily vs. 5-d/wk
Daily vs. 3-d/wk
Daily vs. 2-d/wk
Amenorrheic periods (n = 70)
Daily vs. 5-d/wk
Daily vs. 3-d/wk
Daily vs. 2-d/wk

Lower limit
of agreement
(ng x day/mL) %

Upper limit
of agreement

Proportional
bias

(ng x day/mL)

%

12.0
27.2
67.0

1.4
3.2
8.2

-133.8
-141.8
-136.8

-15.7
-16.8
-16.6

157.9
196.2
270.8

18.6
23.3
32.9

0.0132
0.0140
0.0001

10.0
22.7
65.0

1.0
2.2
6.5

-106.1
-122.1
-127.4

-10.3
-11.9
-12.7

126.1
167.5
257.3

12.2
16.3
25.6

0.6988
0.9908
0.1528

6.6
23.7
50.6

1.2
4.5
9.8

-65.9
-60.4
-84.1

-12.3
-11.5
-16.4

79.1
107.8
185.2

14.8
20.4
36.0

0.4515
0.0405
0.8165

E1G, estrone-1-glucuronide; AUC, area under the curve; d/wk, days per week.
Table 3. Bland-Altman analysis for all menstrual cycle/monitoring period analyses of PdG AUC
Bland-Altman analysis
Mean
difference
Method

(mg x day/mL) %

All cycles and monitoring periods (n = 190)
Daily vs. 5-d/wk
Daily vs. 3-d/wk
Daily vs. 2-d/wk
Eumenorrheic cycles (n = 94)
Daily vs. 5-d/wk
Daily vs. 3-d/wk
Daily vs. 2-d/wk
Amenorrheic periods (n = 70)
Daily vs. 5-d/wk
Daily vs. 3-d/wk
Daily vs. 2-d/wk

Lower limit
of agreement
(mg x day/mL) %

Upper limit
of agreement

Proportional
bias

(mg x day/mL)

%

bias

0.3
1.4
5.1

0.6
2.9
10.8

-8.8
-12.7
-12.4

-17.7
-25.8
-26.3

9.5
15.6
22.7

19.0
31.7
47.9

0.1819
0.4675
0.0000

0.1
1.4
6.2

0.1
2.0
9.6

-12.1
-17.8
-15.8

-17.6
-26.3
-24.3

12.2
20.5
28.3

17.8
30.3
43.4

0.5247
0.3789
0.0541

0.4
1.4
2.8

1.7
5.6
11.8

-3.5
-3.7
-4.4

-13.8
-15.0
-18.2

4.3
6.5
10.1

17.1
26.3
41.8

0.1814
0.0016
0.0314

PdG, pregnanediol glucuronide; AUC, area under the curve; d/wk, days per week.
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aged 24±4.5 years, weighed 57.1±6.0 kg, were 164.5±6.5 cm
tall, and had a BMI of 21.1±1.7 kg/m2. The average age at
menarche was 12.5±.3 years and the mean gynecologic age
was 11.5±4.3 years.
Mixed model analysis
Composite graphs of the average E1G and PdG concentrations, respectively, across the entire cycle for daily, 5- day,
3-day, and 2-day collection frequencies are shown in Figure 5A,B. The classic characteristics of ovulatory cycles,
i.e. the mid-cycle E1G peak and luteal phase PdG peak, are
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evident. The average AUC and cycle mean concentration
for each urinary collection frequency are displayed in inset bar graphs within the composite graphs and in Table
1. There were no significant differences detected between
daily collection and each reduced collection frequency (5
days, 3 days, or 2 days per week) with regard to E1G AUC
(P > 0.46) or mean concentration (P > 0.99). There were
no significant differences detected between daily collection
and each reduced collection frequency (5 days, 3 days, or 2
days per week) with regard to PdG AUC (P > 0.27) or mean
concentration (P > 0.99).

Figure 4. Bland Altman plots for all cycles 20 to 45 days in length and 28-day monitoring periods. The difference between daily and reduced collection frequencies are plotted against the mean of the daily and reduced collection frequency in the 190 paired measurements
from the all cycles/monitoring periods analysis. The comparison of daily and 5 days/week collection frequency is in column 1, daily and 3
days/week collection frequency is in column 2, and daily and 2 days/week collection frequency is in column 3. Differences between daily
and the reduced collection frequencies for E1G mean (A–C) and PdG mean (D–F) are demonstrated.
Table 4. Bland-Altman analysis for all menstrual cycle/monitoring period analyses of E1G mean
Bland-Altman analysis
		
		
Method

Mean
difference
(ng/mL)

Lower limit
of agreement

Upper limit
of agreement

%

(ng/mL)

%

(ng/mL)

%

Proportional
bias

All cycles and monitoring periods (n = 190)
Daily vs. 5-d/wk
Daily vs. 3-d/wk
Daily vs. 2-d/wk

–0.1
-0.2
-0.1

-0.5
-0.8
-0.4

-3.8
-5.2
-6.7

-13.0
-17.7
-22.6

3.6
4.8
6.4

12.1
16.1
21.8

0.9569
0.5725
0.0352

Eumenorrheic cycles (n = 94)
Daily vs. 5-d/wk
Daily vs. 3-d/wk
Daily vs. 2-d/wk

-0.3
-0.5
-0.5

-0.8
-1.4
-1.5

-3.8
-5.3
-7.1

-10.6
-14.7
-19.7

3.3
4.2
6.0

9.1
11.8
16.7

0.4931
0.1312
0.0067

Amenorrheic periods (n = 70)
Daily vs. 5-d/wk
Daily vs. 3-d/wk
Daily vs. 2-d/wk

0.0
0.0
0.0

0.0
-0.2
-0.2

-1.8
-2.9
-5.7

-9.1
-14.3
-28.7

1.8
2.8
5.7

9.1
14.0
28.4

0.5498
0.8204
0.0066

E1G, estrone-1-glucuronide; d/wk, days per week.

366

A l l away e t a l . , A m e r i c a n J o u r n a l o f H u m a n B i o l o g y , 2 7 ( 2 0 1 5 )
Bland Altman analysis

The reduced collection frequencies for eumenorrheic cycles
of 26 to 36 days in length, on average, underestimate the
daily E1G AUC as shown in Table 2. The E1G AUC for all reduced collection frequencies demonstrate good agreement
with daily urine collection as indicated by the 95% LOA including zero. The best agreement is observed with 5-day
collection, indicated by the tighter range for the 95% LOA.
A proportional bias was not observed in any of the reduced
collection frequencies (P > 0.20), as shown in Table 2. As
shown in Table 3, the reduced collection frequencies for eumenorrheic cycles alone, on average, underestimated the
daily PdG AUC. The smallest range for the 95% LOA was observed in the 5-day collection frequency indicating the best
agreement with daily sample collection. A proportional bias
was not observed in any of the reduced collection frequencies (P > 0.050), as shown in Table 3.
Reduction of the collection frequency for eumenorrheic cycles of 26 to 36 days in length, on average, overestimated the E1G mean concentration as shown in Table
4. The 5-day collection frequency demonstrated the lowest degree of overestimation of E1G cycle mean concentration, while the 2-day collection frequency demonstrated the
greatest degree of overestimation. A proportional bias was
not observed in the 5-day and 3-day collection frequencies
(P > 0.10); however, a proportional bias was observed in the
2-day collection frequency (P = 0.007), as shown in Table
4. On average, the daily PdG cycle mean concentration was
overestimated by the reduced collection frequencies for eumenorrheic cycles of 26 to 36 days in length, as shown in Table 5. The best agreement was observed with 5-day collection frequency, indicated by the smaller range for the 95%
LOA. A proportional bias was not observed in the 3-day collection frequency (P = 0.20); however, a proportional bias
was observed in the 5-day and 2-day collection frequencies
(P < 0.030), as shown in Table 5.
Subanalysis of amenorrheic monitoring periods
In a subanalysis of amenorrheic monitoring periods of 28
days there were 19 participants and 70 monitoring periods
with complete data. The participants were aged 21.2±3.5
years, weighed 57.3±7.8 kg, were 165.1±.0 cm tall, and had

a BMI of 21.1±2.4 kg/m2. The average age at menarche was
14.1±1.4 years and the mean gynecologic age was 7±3.9
years.
Mixed model analysis
Composite graphs of the average E1G and PdG concentrations, respectively, across the entire monitoring period for
daily, 5-day, 3-day, and 2-day collection frequencies are
shown in Figure 6A,B. The chronic suppression of E1G and
PdG that is characteristic of reproductive hormone concentrations among amenorrheic women is clearly evident.
Within the inset bar graphs and Table 1, the average AUC
and cycle mean concentrations are displayed for each frequency of urinary collection. There were no significant differences detected between daily collection and each reduced
collection frequency (5 days, 3 days, or 2 days per week)
with regard to E1G AUC (P > 0.12) or mean concentration (P
> 0.99). There were no significant differences detected between daily collection and each reduced collection frequency
(5 days, 3 days, or 2 days per week) with regard to PdG AUC
(P > 0.080) or mean concentration (P > 0.99).
Bland Altman analysis
In amenorrheic 28-day monitoring periods daily sample collection E1G AUC was, on average, underestimated by the reduced collection frequencies (see Table 2). The E1G AUC for
all reduced collection frequencies demonstrate good agreement with daily urine collection as indicated by the 95%
LOA including zero. The best agreement was observed with
the 5-day sample collection frequency, indicated by the
smaller range for the 95% LOA. A proportional bias was
not observed in the 5-day and 2-day collection frequencies (P > 0.20), but a proportional bias was observed in the
3-day collection frequency (P 5 0.04; see Table 2). Daily PdG
AUC was, on average, underestimated by the reduced collection frequencies for 28-day monitoring periods (see Table 3). The smallest range for the 95% LOA was observed
in the 5-day collection frequency, indicating the best agreement with daily sample collection. A proportional bias was
not observed in the 5- day collection frequency (P > 0.20);
however, a proportional bias was observed in the 3-day and
2-day collection frequencies (P < 0.030; see Table 3).

Table 5. Bland-Altman analysis for all menstrual cycle/monitoring period analyses of PdG mean
Bland-Altman analysis
		
		
Method

Mean
difference

Lower limit
of agreement

(ng/mL)

%

All cycles and monitoring periods (n 5 190)
Daily vs. 5-d/wk
Daily vs. 3-d/wk
Daily vs. 2-d/wk

0.0
0.0
0.0

–2.2
–2.1
0.2

Eumenorrheic cycles (n = 94)
Daily vs. 5-d/wk
Daily vs. 3-d/wk
Daily vs. 2-d/wk

–0.1
–0.1
0.0

Amenorrheic periods (n = 70)
Daily vs. 5-d/wk
Daily vs. 3-d/wk
Daily vs. 2-d/wk

0.0
0.0
0.0

PdG, pregnanediol glucuronide; d/wk, days per week.

(ng/mL)

Upper limit
of agreement

Proportional
bias

%

(ng/mL)

%

–0.3
–0.5
–0.6

–16.5
–29.0
–37.3

0.2
0.4
0.7

12.2
24.7
37.7

0.0000
0.0115
0.0635

–2.9
–3.1
–1.3

–.4
–.7
–.9

–16.3
–29.2
–36.2

0.3
0.6
0.8

10.6
23.1
33.5

0.0004
0.2167
0.0296

–0.6
0.7
1.6

–0.1
–.2
–.2

–11.8
–16.9
–26.3

0.1
0.2
0.3

10.5
18.3
29.4

0.2336
0.3317
0.4256
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Figure 5. Composite graphs of urinary reproductive hormone excretion of E1G (A) and PdG (B) for eumenorrheic cycles of 26 to 36 days in
length for daily, 5-day/week, 3-day/week, and 2-day/week urinary collection frequencies. The inset bar graphs depict the cycle AUC and
mean concentration for daily, 5-day/week, 3-day/week, and 2-day/week collection frequencies. Cycle day 1 is the first day of menses. The
data points for the central cycle/monitoring period days have an n 5 94. Cycle/monitoring period days at the beginning and end of the composite graph have a variable “n” due to the varying lengths of the cycles included in the subsample. E1G, estrone-1-glucuronide; PdG, pregnanediol glucuronide; AUC, area under the curve.

The 5-day collection frequency for 28-day monitoring periods, on average, estimated the daily E1G cycle mean concentration, while 3-day and 2-day collection frequencies
overestimated E1G cycle mean concentration (see Table 4).
The calculated E1G cycle mean concentration for all 28-day
monitoring periods and reduced collection frequencies demonstrate good agreement with daily urine collection as indicated by the 95% LOA including zero. A proportional bias
was not observed in the 5-day and 3-day collection frequencies (P > 0.50); whereas, a proportional bias was observed
in the 2-day collection frequency (P < 0.007; see Table 4).
The 3-day and 2-day collection frequencies for 28-day monitoring periods underestimate the daily PdG cycle mean concentration, on average, while the 5-day collection frequency
overestimated the PdG mean cycle concentration (see Table

5). The best agreement is observed with 5-day collection
frequency, indicated by the smaller range for the 95% LOA.
A proportional bias was not observed in any of the reduced
collection frequencies (P > 0.20; see Table 5).
Discussion
The present study was designed to assess the level of agreement between reduced urinary collection frequencies (5
days, 3 days, or 2 days per week) and the urinary gold standard of daily specimen collection in a sample of exercising eumenorrheic and amenorrheic women and in specific
subpopulations of eumenorrheic and amenorrheic exercising women. This report is the first to provide detailed
information on the accuracy and precision of quantifying
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Figure 6. Composite graphs of urinary reproductive hormone excretion of E1G (A) and PdG (B) for 28 day amenorrheic monitoring periods for daily, 5-day/week, 3-day/week, and 2-day/week urinary collection frequencies. The inset bar graphs depict the monitoring period
AUC and mean concentration for daily, 5-day/week, 3-day/week, and 2-day/week collection frequencies. Monitoring period day 1 is the
first day of sample collection. The data points for the monitoring period days have an n = 70. E1G, estrone-1-glucuronide; PdG, pregnanediol glucuronide; AUC, area under the curve.

reproductive hormone exposure using a reduced sampling
schedule. This report supports and builds upon the work of
O’Connor et al. (2006), which tested the presence and day
of ovulation during reduced urinary collection frequencies.
All comparisons between daily collection and each of the
reduced collection frequencies (5 days, 3 days, or 2 days
per week) for the average AUC and mean concentration for
both E1G and PdG were not different when eumenorrheic cycles and amenorrheic monitoring periods were analyzed together and when analyzed separately; however, a difference
was observed between daily collection and 2 days per week
collection frequency with regard to the average E1G AUC in
the complete cycle analysis. In general the 5-day collection

frequency demonstrated the best agreement with daily sample collection in all three analyses. The 3-day and 2-day collection frequencies also showed good agreement with daily
sample collection in all three analyses of exercising women.
The LOA for individual AUC and mean concentrations, however, appeared to increase with reduced sample collection
frequencies. Depending on the required level of accuracy
and precision, researches may choose to use varying sampling frequencies. The present analysis is the first to quantify mean error as well as individual agreement for urinary
reproductive hormones.
The Bland Altman analysis was used to compare the
daily and reduced collection frequencies (Bland and Altman,
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1986). This technique was used to assess the agreement between reduced collection frequencies (5 days, 3 days, or 2
days each week) and daily sample collection. If the differences between the reduced collection frequencies and daily
collection are not large enough to change the interpretation
of the research findings, daily collection could be replaced by
the reduced collection frequencies or the collection frequencies could be used interchangeably. Though there were small
over- or underestimations of the AUC and mean concentrations observed in the Bland Altman analysis, good agreement
among the reduced collection frequencies compared with
daily collection frequency was observed according to the inclusion of zero in the Bland Altman LOA. The Bland Altman
analysis indicated that the AUC for E1G and PdG from reduced urinary collection frequencies were within 9.8% and
11.8% of the daily measures, respectively, in the complete
samples analysis and separate eumenorrheic and amenorrheic analyses. The AUC percent differences would have enabled O’Donnell et al. (2007) and West et al. (2009) to detect the observed 33 to 98% differences in E1G AUC between
sedentary and exercising eumenorrheic women and exercising amenorrheic women. The mean concentrations for
E1G and PdG from reduced urinary collection frequencies
were within 1.5% and 3.1% of the daily measures, respectively, for all three analyses. Differences in mean concentrations between ethnicities, which have been reported to
lie between 1.0 and 22.3% (E1G) and 3.0 and 31.7% (PdG)
(Santoro et al., 2004), would have been observed using 2
days per week as collection frequency. However, observing subtle differences of 1 to 5% in E1G and PdG AUC, as
reported between sedentary and exercising eumenorrheic
women (O’Donnell et al., 2007; West et al., 2009) would require the urinary collection frequency to be no fewer than
3 days per week (3.2% for E1G and 2.9% for PdG mean percent difference). Use of reduced urinary collection frequencies as few as 2 days per week to assess group differences
in cycle AUC and mean concentration provides comparable
values to daily urinary collection. Thus, the use of reduced
collection frequencies would still allow detection of differences between experimental groups.
In a study by Mumford et al. (2012) 8 serum samples
were collected during biologically relevant windows timed
to a standardized 28-day menstrual cycle. The serum samples were utilized to assess the exposure to reproductive
hormones in women with short (<26 days), normal (26–35
days), and long (>35 days) menstrual cycle lengths. Unfortunately, the authors did not conduct a comparison of the eight
samples to daily sampling, but the AUC values presented by
Mumford et al. (2012) demonstrated a high standard error
indicating eight samples per menstrual cycle to be too large
a reduction in sample collection. The authors commented
that collecting only eight serum samples throughout the
menstrual cycle reduced the generalizability of their findings in women with longer and more irregular cycles (Mumford et al., 2012). The basic shape of the E1G and PdG curves
across the menstrual cycles in our analysis indicate that reducing the urinary collection frequency as low as eight samples per cycle (2 days per week in a 28-day menstrual cycle
or monitoring period) increases the likelihood of missing the
peak hormonal concentrations, thus greatly altering the AUC
and mean concentration calculations. In our analysis a reduced collection frequency of less than 5 days per week was
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associated with an increased range for the LOA due to the
potential of missing peak hormonal concentrations, which
may also compromise the use of reduced collection frequencies in studies evaluating individual subjects and clinical
outcomes, such as day of ovulation.
The shape and timing of the peaks of E1G and PdG greatly
affect the determination of exposure and cycle mean concentration. For example, the E1G peak is generally narrow and
rises quickly to a peak, while the PdG peak is a broad curve.
Hence, the narrow peak for E1G is more likely to be missed
by a reduced sample collection frequency compared with the
peak of a broad curve, like PdG. Differences in capture of the
E1G and PdG peaks are shown in the composite graphs (Figs.
2, 5, and 6). Figure 5 shows that the broad PdG peak was not
influenced by the reduced collection frequencies; however,
the shape of the E1G peak is varied, though not visually different, between the reduced collection frequencies and daily
collection hormone profile. Within a group analysis a proportion of the narrow peaks would be captured with the reduced collection frequencies, thus the increased LOA; however, when analyzing a cycle from an individual participant
it is highly likely the E1G peak concentration would have occurred on a non-sample collection day. When evaluating individual cycles for a case report, as seen with Mallinson et
al. (2013), a reduction in the collection frequency as low as
2 days per week would not influence the characterization
of the cycle via hormonal exposure in a participant who has
had amenorrhea for a long period of time. In a participant
who had amenorrhea for a short period of time a reduction
in sample collection to 2 days a week would underestimate
the exposure of the participant to reproductive hormones
due to higher variations in monitoring period peaks of E1G
and PdG across a year (Mallinson et al., 2013b).
Urinary samples are self-collectable, noninvasive, can be
easily stored and transported, and have been shown to tolerate a wide variety of non-perfect experimental conditions
in the field (O’Connor et al., 2006; Kesner et al., 1995). Initially it was assumed that daily samples could be collected
for prolonged periods of time with a high degree of compliance, however, many recent studies have shown compliance
to be highly variable depending on study length (Kesner et
al., 1992; Kravitz et al., 2005; Liu et al., 2004; Santoro et
al., 1996; Waller et al., 1998; Wright et al., 1992). The level
of compliance to sample collection may be due to personal
or housemate comfort level with storage of specimens or
ability to store samples when away from the primary residential address. Participants in early studies which evaluated perceptions of urinary sample collection reported that
the benefits of increased knowledge about their body outweighed the uncomfortable nature of urine collection (Wilcox et al., 1987; Wright et al., 1992). According to Wright et
al. (1992), urine collection was one of the least objectionable of the eight methods used to assess reproductive function (transvaginal ultrasound, basal body temperature, salivary electrical resistance, blood sampling, salivary samples,
vaginal mucus electrical resistance, and manual cervical mucus consistency). The study by Wright et al. (1992) was one
of the first to assess the attitudes of the general population, instead of nurses, to reproductive hormone collection
methods. Anecdotal evidence from our laboratory has indicated that participant travel over weekends and for vacations lead to large gaps in sample collection and decreased
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compliance, thus the reduced collection frequencies evaluated in this article provided the participants with weekends
free from sample collection. In fact, for this analysis we excluded 67% of available cycles due to reduced compliance.
In studies of long duration it is unavoidable to have participants run into vacation time such as Thanksgiving, family
summer holidays, or winter break, when reduced compliance to sample collection is more likely to occur.
One limitation of the present analysis was the restriction
of the data set to only include subjects who were 100% compliant to the reduced collection frequencies. The presence of
missed collection days within the reduced sample collection
frequencies would decrease the accuracy of the urinary reproductive hormone metabolite profile across the menstrual
cycle or monitoring period. Reduced collection frequency
strategies still require the use of a valid menstrual cycle calendar in order to create an accurate presentation of the hormonal profile. Not all urinary collections for eumenorrheic
cycles will begin on the first day of the menstrual cycle nor
will the final collection always be on the last day of the menstrual cycle. Another limitation of the study was that we did
not evaluate clinical reproductive outcomes in this analysis;
however, such outcomes are integral in the usefulness of reduced collection frequencies. Future studies should evaluate
the validity of the reduced collection frequencies evaluated
in this article in detecting luteal sufficiency and assessing
this strategy in an independent sample.
The strengths of this analysis are that there were a large
number of cycles included, individual participants provided
multiple cycles, and the cycles used for reducing the collection frequency were based on menstrual cycles, and 28-day
monitoring periods that had all samples collected. In the
data set, there are near equal numbers of short, normal,
and long menstrual cycles in the eumenorrheic participant
cycles and 28-day monitoring periods. Within our eumenorrheic cycles we intentionally included all cycle classifications (LPD, anovulatory, and ovulatory cycles) to show that
even with cycles of highly variable hormone levels the reduced collection frequencies continue to have good agreement with daily urinary sample collection.
Though daily urinary collection is the most accurate reflection of reproductive hormone production when using urinary analysis, our results demonstrate that accurate E1G
and PdG profiles of menstrual cycles of various lengths (20–
45 days) and types (eumenorrheic and amenorrheic) can
be measured with reduced urinary collection frequencies.
This work supports and builds on the work of O’Connor et
al. (2006) demonstrating that a reduced sampling schedule
can provide useful and accurate information in a manner
that is comparable to that obtained from daily sampling of
urine regarding ovarian hormone exposure and mean concentrations. The accuracy in quantifying exposure allows reduced collection frequency strategies to be utilized in under
researched populations and in less developed regions around
the world, where the capacity to store samples in a cold environment may be limited. The reduced collection frequencies produced composite E1G and PdG profiles for an entire
cycle or monitoring period that were similar to the composite graphs of daily urinary collection. We have shown
that daily ovarian steroid levels are not necessarily required
to quantify AUC or mean values E1G or PdG across the entire menstrual cycle or monitoring period when conducting

group examinations for the assessment of disease risk, such
as osteoporosis, endothelial dysfunction, ovarian cancer,
and breast cancer, in large populations. Further research is
needed to evaluate whether clinical outcomes, such as luteal sufficiency, are possible to determine through these specific reduced collection frequencies. We suggest reducing the
urinary collection frequency in an effort to reduce the participant burden, increase compliance, and decrease project
costs, depending on the accuracy and precision required to
answer the reproductive questions of interest.
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